WHAT WE KNOW: The Whole Signalling Fraction Stays Together
Blood does not deliver a single molecule to injured tissue. It delivers a mixture — vesicles, growth factors, signalling proteins and the plasma proteins that carry and protect them — and they arrive together because that is how the body sends them.
Almost every preparation in this field takes that mixture apart. A platelet concentrate keeps the platelets and discards the plasma around them. A vesicle isolation keeps the vesicles and washes the proteins away, because the membranes used for that job pass everything below several hundred kilodaltons. Each of those choices throws away a fraction that was there for a reason.
exosmart™ makes the opposite choice. The membrane holds back everything above roughly 15 kilodaltons, so the vesicles, the platelets, the growth factors, the signalling molecules and the larger plasma proteins all stay in and are concentrated together.
exosmart™ is used by a doctor as part of a procedure. Blood is taken, the plasma is prepared, and a trained doctor gives the concentrate to the patient. Any procedure involving a needle in a vein and a needle in tissue carries risk, and the preparation is not suitable for every patient. The instructions for use set out which patients should not be treated, what to watch for, how to select patients and how to handle the device, and the doctors' training covers all of it.
In a prospective study of 30 patients in Alessandria there were no serious adverse events.
Nothing is separated out, nothing is purified, and nothing is selected. The patient's own plasma goes in whole and comes back concentrated and whole. This is the complete secretome, and keeping it intact is the design rather than a limitation of it.
The preparation is autologous throughout, and no chemical activator is added.
WHAT WE DO NOT KNOW
How much of each individual component ends up in the final preparation. Concentration is a volume relationship, and some protein is always lost to the membrane surface and to the volume held inside the device. We have not measured recovery component by component, so we do not put a single multiplication figure on it.
WHAT WE KNOW: The wider research, and why it is not a verdict on this device
Autologous platelet preparations have been studied for thirty years, in thousands of patients, across orthopaedics, dermatology, hair and gynaecology. Some trials found meaningful benefit. Others, well designed and properly controlled, found none. Both belong in the same module, and in this Academy they get the same weight and the same size type.
Professional bodies disagree with each other about the same evidence. What is worth noticing is the reason those recommending against give: not that these preparations were shown not to work, but that the studies are of variable quality and the preparations themselves have never been standardised. That reasoning cuts in both directions. If the class is too varied for its positive trials to settle the question, it is equally too varied for a negative class finding to settle it for a preparation made a different way — and by the same logic we cannot claim the positive trials as ours either.
Whether results from any of that literature transfer to this device. They were produced with different preparations, different concentrations and different protocols. We teach them as what they are — evidence about platelet-rich plasma — and never as evidence about exosmart™.
